PCSK9 and diabetes mellitus: Furthermore, the use of non-statin lipid-lowering drugs significantly increased diabetes risk by 1.31 times, although research does not conclusively show that non-statin lipid-lowering drugs increase diabetes risk, such as a study published in Curr Cardiol Rep in 2016 [34], which found that niacin increased diabetes risk, whereas PCSK9 inhibitors, ezetimibe, and fibrates did not increase risk, a finding also supported by a study in Drug Context in 2018 [35].